DexCom is in a sustained, powerful uptrend that has recovered decisively from a deep drawdown. The stock is up 29.72% over the trailing year and 29.31% year to date, and at $86.04 it sits at roughly 83.9% of its 52-week range of $54.11 to $92.59 — near the upper end but not at the highs, implying momentum remains intact without being maximally extended. The maximum drawdown of -28.36% over the period underscores that this is a recovery trend off a meaningful base rather than a low-volatility grind higher, and the current price is about 7.1% below the 52-week high, leaving room before resistance is tested.

Short-term momentum has decelerated even as the longer-term trend stays positive, creating a modest divergence. The stock is down 1.49% over the past month and fell 1.90% on the most recent session (from $87.71 to $86.04), while the 3-month change remains a healthy +12.25% and the 6-month change is +34.48%. Relative strength tells the same story: DexCom has outperformed the S&P 500 by 14.19 percentage points over one year and 9.56 points over three months, but has lagged the index by 2.71 points over the past month (versus SPY's +1.22%). This pattern — strong medium-term outperformance with a flat-to-negative recent month — is characteristic of consolidation after a sharp run rather than a trend reversal, particularly since the pullback has been orderly and the stock remains well above its 3-month and 6-month averages.

Key technical levels are well defined. Support sits at the 52-week low of $54.11, with a more relevant near-term floor in the high-$70s to low-$80s where the stock consolidated in August and September; resistance is the 52-week high of $92.59, and a breakout above that level would confirm the recovery trend and likely trigger momentum-driven buying. A breakdown below the $80 area would signal that the post-earnings gap (the stock jumped from $74.54 on July 30 to $83.45 on July 31) is failing and would put the $70s back in play. With a beta of 1.477, DexCom is roughly 48% more volatile than the market, meaning position sizing should account for amplified moves in both directions; the short ratio of 3.52 days-to-cover is moderate and does not suggest a crowded short base that would fuel a squeeze.

DexCom's revenue trajectory has reaccelerated meaningfully. Q2 2026 revenue of $1.308 billion grew 13.08% year over year versus $1.157 billion in Q2 2025, and the sequential progression from Q1 2026's $1.192 billion (+15.1% YoY versus $1.036 billion) shows growth running in the low-to-mid teens. The multi-quarter trend is one of steady acceleration: quarterly revenue climbed from $1.036 billion (Q1 2025) to $1.157 billion, $1.209 billion, $1.260 billion, $1.192 billion, and $1.308 billion, with the Q1 2026 dip reflecting normal seasonality rather than deterioration. This reacceleration, combined with the Stelo pediatric expansion and international rollout, supports a growth case that is improving rather than maturing, though the 13% rate is a step down from the 20%+ growth DexCom delivered in earlier years and reflects a larger base and competitive pricing.

Profitability has inflected sharply upward. Q2 2026 net income was $249.1 million (a 19.0% net margin) on gross profit of $830.0 million, a 63.44% gross margin that expanded from 59.53% in Q2 2025 and 62.95% in Q1 2026. Operating income reached $318.3 million (24.3% operating margin) versus $212.6 million (18.4%) a year earlier, and EBITDA rose to $388.7 million (29.7% EBITDA margin) from $308.8 million. The margin expansion is being driven by operating leverage — R&D of $153.0 million grew only 3.2% YoY while revenue grew 13.1% — and by gross margin gains from manufacturing efficiencies; the trailing twelve-month net margin of 17.94% and operating margin of 19.56% confirm the company has moved well past its 2024 margin trough.

Balance sheet and cash flow metrics are solid but not pristine. Debt-to-equity is a manageable 0.506, the current ratio is 1.88, and interest coverage is exceptionally high (interest expense of just $3.0 million against $318.3 million of operating income), indicating negligible financial risk from leverage. Free cash flow is robust at $1.405 billion trailing twelve months, and Q2 2026 free cash flow of $184.5 million was generated alongside $84.7 million of capex and $603.6 million of share repurchases — evidence the company can fund growth, buy back stock, and still grow cash. ROE of 30.46% and ROA of 10.33% are strong, though the FCF yield of roughly 5.4% (on a $25.9 billion market cap) and PCF ratio of 17.98 suggest the market is paying up for that cash generation; the main watch item is the elevated inventory days (136.7) and cash conversion cycle (145.2 days), which bear monitoring for working-capital efficiency.